At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.
Close
PALI Palisade Bio Inc.
Pre-Market Trading 05-21 06:07:21 EDT
5.85
-0.51
-8.02%
High6.29
Low5.66
Vol72.62K
Open6.25
D1 Closing6.36
Amplitude9.88%
Mkt Cap5.48M
Tradable Cap5.39M
Total Shares937.56K
T/O429.13K
T/O Rate7.89%
Tradable Shares920.90K
P/B--
ROE--
EPS0.00
52wk High--
52wk Low--
P/E--
Dividend--
Div.Yield--
ROA--
Buy Rating Affirmed for Palisade Bio’s PALI-2108 Amid Strong Financials and Promising Partnership
Palisade Bio’s Lead Product Candidate, PALI-2108 Demonstrates Potent Anti-Inflammatory Effects in Ex-Vivo Study of Whole Blood Samples Challenged with Pro-Inflammatory Lipopolysaccharide (LPS)
Palisade Bio, Inc., a clinical-stage biopharmaceutical company, focuses on focuses on developing therapeutics that protect the integrity of the intestinal barrier in the United States. The company's lead therapeutic candidate is LB1148, an oral liquid formulation of the digestive enzyme inhibitor tranexamic acid to reduce the formation of postoperative adhesions, postoperative ileus, and return of bowel function in adults. It has a license agreement with the Regents of the University of California; and co-development and distribution agreement with Newsoara Biopharma Co., Ltd. Palisade Bio, Inc. is based in Carlsbad, California.